Patients Overpay For Prescriptions 23% Of The Time, Analysis Shows
Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.
Drug Costs
541 - 560 of 703 Results
-
-
Rising Health Costs, Soaring Drug Prices, Confusing Bills! What’s A Consumer To Do?
KHN correspondent Shefali Luthra answered a wide variety of questions about health care in a Reddit “Ask Me Anything” chat.
-
Podcast: KHN’s ‘What The Health?’ HHS Leaders Take To The Stump
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
-
Of ‘Miracles’ And Money: Why Hemophilia Drugs Are So Expensive
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.
By Jenny Gold -
States Strive To Curb Costs For A Crucial — But Exorbitant — Hemophilia Treatment
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
-
Cartoon Mascot Masks Nasty Health Care Feud
California’s health insurers trotted out a heart-healthy character with an ulterior motive — taking a dig at drugmakers.
-
In An Effort To Curb Drug Costs, States Advance Bills To Prod Feds On Importation
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
-
FDA Head Vows To Tackle High Drug Prices And Drugmakers ‘Gaming The System’
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
By Sarah Jane Tribble and Liz Szabo -
Trump’s Budget Proposal Swings At Drug Prices With A Glancing Blow
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
-
KHN On NPR: The Uniquely American Problem Of High Prescription Drug Costs
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR's Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
-
Podcast: KHN’s ‘What The Health?’ There’s A Really Big Health Bill In That Budget Deal
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump’s upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called “The United States of Care.”
-
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
By Jay Hancock and Shefali Luthra -
Podcast: KHN’s ‘What The Health?’ The State Of The (Health) Union
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump’s promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
-
Expert Advice For The Corporate Titans Taking On Health Care
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
-
States Face Costly Conundrum: How To Treat Inmates With Hepatitis C
Although the potentially fatal disease is common among the incarcerated, treatment with the latest hepatitis drugs isn't.
-
Podcast: What The Health? Our First Live Show: What The Health Will Happen In 2018?
In this episode of “What The Health?” — taped before a live audience — panelists discuss the potential federal government shutdown and what may be in store for health in 2018. They are joined by former Medicare and Medicaid head Tom Scully.
-
Fallout From ‘Nuclear Button’ Tweets: Sales Of Anti-Radiation Drug Skyrocket
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Korea’s Kim Jong-un.
-
Facebook Live: It’s 2018, Can Big Pharma Hold The Line Against Pricing Controls?
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
-
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
-
From Retirement To The Front Lines Of Hepatitis C Treatment
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.